Harrow Health, Inc.
NASDAQ:HROWDrug Manufacturers - Specialty & Generic
+$0.12 today
- Market cap
- $1.21B
- Beta
- 0.28
- P/E (TTM)
- -104.7
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.75M
HROW Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Harrow Health, Inc.NASDAQ: HROW
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue grows, but more slowly than its trailing trend
Q1 FY2026 cost of revenue of $17.16M rose 10.5% year over year, behind the +28.3% change in trailing-twelve-month cost of revenue. Sequentially, it fell 7.1% from the prior quarter. Over 3 fiscal years it compounded at +38.8% a year.
Context
- Cost of revenue amounted to 24.9% of revenue in FY2025, up 0.3 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +10.5% toward the trailing-twelve-month pace of +28.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 67.93M USD
- Year-over-year change
- +38.0%
- 4-year CAGR
- +39.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.93M | +38.0% |
| FY2024 | 2024-12-31 | 49.25M | +24.2% |
| FY2023 | 2023-12-31 | 39.64M | +56.2% |
| FY2022 | 2022-12-31 | 25.38M | +39.4% |
| FY2021 | 2021-12-31 | 18.21M | — |
Cost of Revenue vs competitors
How HROW compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +28.3% is the 3rd highest of 7, against a peer median of +13.7%.
- Cost of revenue amounts to 25.9% of revenue for HROW, versus a peer median of 71.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $2.28B USD | +8.0% | +15.0% | 42.8% | |
| LTM Sep 2026 | $678.51M USD | +1556.2% | +217.9% | 99.5% | |
| LTM Mar 2026 | $69.57M USD | +28.3% | +38.8% | 25.9% | |
| LTM Mar 2026 | CHF 15.07M CHF | — | — | 2989.4% | |
| LTM Mar 2026 | $6.64M USD | +19.4% | +13.1% | 12.8% | |
| LTM Mar 2026 | $1.79M USD | -52.4% | -37.2% | 23.5% | |
| LTM Mar 2026 | $1.54M USD | +977.1% | +54.6% | 460.9% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $42.29K USD | — | — | — |
| LTM Sep 2026 | $0 USD | -100.0% | — | — | |
| Peer median (excluding HROW) | — | +13.7% | +15.0% | 71.1% | |
Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 72.48M | 88.6M | 130.19M | 199.61M | 272.3M |
| Cost of Revenue | 18.21M | 25.38M | 39.64M | 49.25M | 67.93M |
| Gross Profit | 54.26M | 63.21M | 90.55M | 150.37M | 204.37M |
| Gross Margin | 74.9% | 71.3% | 69.6% | 75.3% | 75.1% |
| Research & Development | 11.08M | 3.05M | 6.65M | 12.23M | 12.85M |
| Selling, General & Admin | 39.82M | 0 | 0 | 0 | 152.91M |
| Operating Expenses | 52.65M | 61.29M | 90.12M | 141.55M | 165.76M |
| Depreciation & Amortization | 1.74M | 2.83M | 11.14M | 13.05M | 18.91M |
| EBITDA | 5.1M | (3.94M) | 11.95M | 22.13M | 41.36M |
| EBITDA Margin | 7.0% | -4.4% | 9.2% | 11.1% | 15.2% |
| Operating Income | 1.61M | 1.92M | 431K | 8.82M | 38.61M |
| Operating Margin | 2.2% | 2.2% | 0.3% | 4.4% | 14.2% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.44M | 7.24M | 21.32M | 22.79M | 24.18M |
| Other Income / Expenses | (19.49M) | (15.93M) | (24.14M) | (26.14M) | (40.33M) |
| Income Before Tax | (17.87M) | (14.01M) | (23.71M) | (17.32M) | (1.72M) |
| Pre-Tax Margin | -24.7% | -15.8% | -18.2% | -8.7% | -0.6% |
| Income Tax Expense | 133K | 75K | 701K | 161K | 3.42M |
| Net Income | (18.01M) | (14.09M) | (24.41M) | (17.48M) | (5.14M) |
| Net Margin | -24.8% | -15.9% | -18.7% | -8.8% | -1.9% |
| EPS (Basic) | (0.69) | (0.51) | (0.75) | (0.49) | (0.14) |
| EPS (Diluted) | (0.69) | (0.51) | (0.75) | (0.49) | (0.14) |
| Weighted Avg Shares | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
| Weighted Avg Shares (Diluted) | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
Harrow Health, Inc.
NASDAQ:HROW
Intrinsic Alpha fair value
Locked
Current Price
$32.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.